Q3 2023 Results - Reimagining Medicine
Company overview
Financial review
Conclusions
Appendix
References
FINANCIAL PROFILE
Significant improvement in core margin for continuing operations
Q3 2023
Core operating
Net sales
change vs. PY1
income
change vs. PY1
Core margin Core margin
(in % cc)
(in % cc)
(%)
change vs. PY1
(%pts cc)
Net sales
change vs. PY1
9M 2023
Core operating
income
change vs. PY1
Core margin¹ Core margin
change vs. PY1
(in % cc)
(in % cc)
(%)
(%pts cc)
Continuing
operations²
12
21
37.4
2.7
10
19
36.9
2.9
Discontinued
operations²
6
-38
10.1
-9.3
8
-11
16.0
-3.7
Group
9
14
33.8
1.3
9
15
34.1
2.0
1. Constant currencies (cc), core results are non-IFRS measures. Explanation of non-IFRS measures can be found on page 48 of the Condensed Interim Financial Report 2. As defined on page 37 of the Condensed Interim Financial Report,
Continuing operations include the retained business activities of Novartis, comprising the Innovative Medicines Division and the continuing Corporate activities and Discontinued operations include operational results from Sandoz business.
25 Investor Relations | Q3 2023 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation